Spots Global Cancer Trial Database for mpdl3280a
Every month we try and update this database with for mpdl3280a cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | NCT03272217 | Urothelial Carc... | Atezolizumab Bevacizumab | 18 Years - | Hoosier Cancer Research Network | |
| MPDL3280A With Chemoradiation for Lung Cancer | NCT02525757 | Lung Cancer Non-Small Cell ... | MPDL3280A Carboplatin Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | NCT02748889 | Small Cell Lung... | Carboplatin Etoposide MPDL3280A | 18 Years - | Georgetown University | |
| A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | NCT02951767 | Bladder Cancer | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | NCT02314481 | Non-small Cell ... | MPDL3280A Vemurafenib Alectinib Trastuzumab emt... | 18 Years - | University College, London | |
| Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | NCT02716038 | Carcinoma, Non-... | MPDL3280A Carboplatin Nab-paclitaxel | 18 Years - | Columbia University | |
| A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma | NCT03519295 | Anal Cancer | MPDL3280A mDCF | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| MPDL3280A-treatment-IST-UMCG | NCT02478099 | Locally Advance... | MPDL3280A | 18 Years - | University Medical Center Groningen | |
| Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | NCT02495636 | Non-Small Cell ... | CDX-1401 MPDL3280A | 18 Years - | Yale University | |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | NCT02748889 | Small Cell Lung... | Carboplatin Etoposide MPDL3280A | 18 Years - | Georgetown University | |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | NCT02748889 | Small Cell Lung... | Carboplatin Etoposide MPDL3280A | 18 Years - | Georgetown University | |
| A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | NCT02463994 | Non-small Cell ... | MPDL3280A Hypofractionate... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma | NCT03519295 | Anal Cancer | MPDL3280A mDCF | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 | NCT02620280 | Invasive Ductal... | Carboplatin Abraxane MPDL3280A Surgery Anthra | 18 Years - | Fondazione Michelangelo | |
| Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 | NCT02620280 | Invasive Ductal... | Carboplatin Abraxane MPDL3280A Surgery Anthra | 18 Years - | Fondazione Michelangelo | |
| Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | NCT02495636 | Non-Small Cell ... | CDX-1401 MPDL3280A | 18 Years - | Yale University | |
| A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | NCT02630186 | Non-small Cell ... | Rociletinib MPDL3280A | 18 Years - | Clovis Oncology, Inc. | |
| A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | NCT02463994 | Non-small Cell ... | MPDL3280A Hypofractionate... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder | NCT02662309 | Bladder Cancer | MPDL3280A | 18 Years - | Queen Mary University of London | |
| A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | NCT02951767 | Bladder Cancer | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| MPDL3280A-treatment-IST-UMCG | NCT02478099 | Locally Advance... | MPDL3280A | 18 Years - | University Medical Center Groningen | |
| Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | NCT02716038 | Carcinoma, Non-... | MPDL3280A Carboplatin Nab-paclitaxel | 18 Years - | Columbia University | |
| A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | NCT02630186 | Non-small Cell ... | Rociletinib MPDL3280A | 18 Years - | Clovis Oncology, Inc. | |
| A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | NCT02951767 | Bladder Cancer | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| MPDL3280A With Chemoradiation for Lung Cancer | NCT02525757 | Lung Cancer Non-Small Cell ... | MPDL3280A Carboplatin Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
